A drug manufacturer specializing in novel and scalable cell therapy, gene therapy, and vaccine production.

The COVID-19 pandemic exposed major supply chain and manufacturing bottlenecks in biologics production, which highlight the need for innovation in the production of complex therapeutics. Resilience aims to create an ecosystem for advanced biologics manufacturing by leveraging innovative, flexible, and scalable production techniques to ensure access to cell therapy, gene therapy, and other novel therapeutics.  Unlike traditional CDMOs, Resilience’s ecosystem also aims to offer best-in-class quality and regulatory capabilities at all stages of the drug development process so that their pharmaceutical partners can focus more time and effort on discovering the drugs of tomorrow.